Skip to main content

Supply Chain

By Rene Letourneau | 10:00 am | February 01, 2012
For every dollar spent on over-the-counter (OTC) medicines, the U.S. healthcare system saves six to seven dollars, providing $102 billion in value annually, says a new report from the Consumer Healthcare Products Association (CHPA).
By Rene Letourneau | 09:44 am | January 31, 2012
Doctors' lack of brand loyalty costs Big Pharma billions of dollars annually because doctors prescribe generics as soon as they become available, says a new survey from marketing solutions firm DoctorDirectory.
By Chris Anderson | 09:44 am | January 30, 2012
The Federal Trade Commission filed a lawsuit Friday seeking to block long-term care pharmacy services company OmniCare Inc.'s hostile takeover attempt of rival PharMerica Corp.
By Rene Letourneau | 08:24 am | January 27, 2012
New drugs in three multi-billion dollar categories will help pharmaceutical companies offset patent expirations and will ease pressure on credit rating outlooks, says a new report from Moody's Investors Service.
By Stephanie Bouchard | 10:23 am | January 26, 2012
India's largest drug manufacturer, Ranbaxy Laboratories and its U.S. subsidiary, Ranbaxy Inc., and the U.S. Justice Department, and U.S. Food and Drug Administration have reached an agreement over allegations that the company was selling potentially unsafe drugs in the United States.
By Bernie Monegain | 10:50 am | January 24, 2012
UPMC attempts to reduce supply chain expenses by using an electronic data interchange.
By Rene Letourneau | 09:03 am | January 20, 2012
Genetic and genomic clinical laboratory testing generates 116,000 U.S. jobs and contributes $16.5 billion annually to the U.S. economy, according to a new report released Thursday by the Battelle Memorial Institute.
By Rene Letourneau | 10:01 am | January 18, 2012
The market for stem cell technologies will rise to over $700 million this year, and given some positive trends, could reach over $1 billion, according to healthcare market research publisher Kalorama Information.
By Rene Letourneau | 02:14 pm | January 06, 2012
The U.S. market for orthopedic biomaterials will grow at an average of just under 7 percent per year, to total approximately $4 billion by 2016, predicts medical technology market research firm Millennium Research Group (MRG).
By Rene Letourneau | 10:00 am | January 03, 2012
Contrary to federal law, CMS accepted $15.1 million in gross drug costs for prescriptions written by excluded providers from 2006 to 2008 under the Medicare Part D program, according to a recent report from the Office of Inspector General.